Antiretroviral Therapy) efficacy and safety of Contact for further simplifying therapy from a information: Eligibility: regimen of atazanavir (ATV) + Daniel Guzman, CRC Men and women > ritonavir (RTV) + 305/538-1400 ext: 222 18 years of age. 1) TDF/3TC + ATV/r tenofovir/emtricitabine (300/100 mg) must be patient’s initial (TDF/FTC) to a regimen of ATV + antiretroviral regimen or the first or abacavir sulfate/lamivudine second switch regimen, 2) virologically (ABC/3TC) without RTV in suppressed on TDF/FTC + ATV/r, 3) must virologically suppressed, HIV-1 be HLA-B*5701 negative. infected subjects. Salix Pharmaceuticals – P.I.: Michael Wohlfeiler, Enrollment open Trials for HIV-Associated Conditions CFHD3092: This study is being M.D. Trials for HIV-Associated conducted to evaluate the Eligibility: Conditions safety and tolerability of Contact for further HIV-infected adults who have been on crofelemer 125 mg twice a day, information: antiretroviral therapy for at least 4 weeks taken orally, over 48 weeks of Daniel Guzman, CRC prior to screening with self-reported therapy in human 305/538-1400 ext: 222 presence of diarrhea immunodeficiency virus-positive (HIV+) subjects with diarrhea. Miami Beach Community Health Center, Inc. KOWA Research Institute – P.I.: Mark Keller, M.D. Enrollment open Trials for HIV-Associated Conditions NK-104-4.05US: A study Trials for HIV-Associated comparing Pitavastatin (4 mg.) Contact for further E ligibility: Conditions vs. Pravastatin (40 mg.) in information: HIV-infected men and women, ages 18-70, subjects with Alice Lopez who have taken antiretroviral drugs for at 305/866-8915 least 6 months. LDL > 130 mg. and < 220 dyslipidemia. mg. and triglyceride levels < 400. , AIDS Clinical Research Unit , Room 2016
Antiretroviral Therapy) efficacy and safety of simplifying therapy from a regimen of atazanavir (ATV) + ritonavir (RTV) + tenofovir/emtricitabine (TDF/FTC) to a regimen of ATV + abacavir sulfate/lamivudine (ABC/3TC) without RTV in virologically suppressed, HIV-1 infected subjects. Contact for further information: Daniel Guzman, CRC 305/538-1400 ext: 222 Eligibility: Men and women > 18 years of age. 1) TDF/3TC + ATV/r (300/100 mg) must be patient’s initial antiretroviral regimen or the first or second switch regimen, 2) virologically suppressed on TDF/FTC + ATV/r, 3) must be HLA-B*5701 negative. Trials for HIV-Associated Conditions Salix Pharmaceuticals – CFHD3092: This study is being conducted to evaluate the safety and tolerability of crofelemer 125 mg twice a day, taken orally, over 48 weeks of therapy in human immunodeficiency virus-positive (HIV+) subjects with diarrhea. P.I.: Michael Wohlfeiler, M.D. Contact for further information: Daniel Guzman, CRC 305/538-1400 ext: 222 Enrollment open Trials for HIV-Associated Conditions Eligibility: HIV-infected adults who have been on antiretroviral therapy for at least 4 weeks prior to screening with self-reported presence of diarrhea Miami Beach Community Health Center, Inc. Trials for HIV-Associated Conditions KOWA Research Institute – NK-104-4.05US: A study comparing Pitavastatin (4 mg.) vs. Pravastatin (40 mg.) in subjects with dyslipidemia. P.I.: Mark Keller, M.D. Contact for further information: Alice Lopez 305/866-8915 Enrollment open Trials for HIV-Associated Conditions E ligibility: HIV-infected men and women, ages 18-70, who have taken antiretroviral drugs for at least 6 months. LDL > 130 mg. and < 220 mg. and triglyceride levels < 400. , AIDS Clinical Research Unit , Room 2016
12-31-12%20FCHAR%20Inventory.docx